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OBJECTIVES We examined whether activated protein C (APC) is an effective conjunctive therapy to
thrombolysis in patients with ST-segment–elevated acute myocardial infarction (AMl).
BACKGROUND Activated protein C possesses both systemic anticoagulant and anti-inflammatory properties.
It has been also shown to enhance fibrinolysis by inhibiting plasminogen activator inhibitor
(PAI) activity in vitro.
METHODS After successful thrombolysis with alteplase, study patients were assigned to receive one of the
two conjunctive therapies for 48 h intravenously: human plasma-derived APC at 0.06 mg/kg
per day (APC group, n  9) or unfractionated heparin at 100 to 400 U/kg per day, adjusted
to maintain an activated partial thromboplastin time at 1.5 to 2 times of the control level
(heparin group, n  10).
RESULTS Adverse events, including reocclusion of the recanalized infarct-related coronary artery and
major or minor hemorrhagic complications, occurred more frequently in the heparin group (4
of 10 cases) than in the APC group (none of 9 cases) (p  0.033). In the heparin group,
plasma PAI activity (IU/ml, median value [range]) was increased continuously from 8 to 24 h
after thrombolysis and peaked at 24 h (30.9 [11.3 to 38.5]); on the other hand, it was not
increased in the APC group at 24 h after thrombolysis (11.3 [0.0 to 31.0], p  0.01 vs.
heparin group).
CONCLUSIONS Administration of APC suppressed increasing of plasma PAI activity observed after
thrombolysis in patients with AMI. The effect of APC could be more eligible, compared with
heparin, as a conjunctive regimen to thrombolysis in AMI patients. (J Am Coll Cardiol
2003;42:1389–94) © 2003 by the American College of Cardiology Foundation
Protein C is one of the most important physiologic antico-
agulant components (1,2). After activation by thrombin–
thrombomodulin complexes on the membrane surface of
platelets and endothelial cells, protein C is converted to
activated protein C (APC), which inactivates factors Va and
VIIIa (3,4). These properties of APC are thought to be
eligible for a therapeutic strategy against thrombotic disor-
ders. In fact, APC has favorable effects on a murine model
of ischemic stroke (5) and a rat model of mesenteric
arteriolar thrombosis (6). Activated protein C has also been
shown to inactivate type 1 plasminogen activator inhibitor
(PAI-1), thereby promoting fibrinolysis (7,8). When re-
leased from activated platelets, PAI-1 is thought to be
involved in the formation of microthrombus by inhibiting
clot lysis (9), and that may cause reocclusion of coronary
arteries after thrombolytic therapy in patients with acute
myocardial infraction (AMI).
We have previously demonstrated that APC is more
effective than heparin in preventing arterial reocclusion after
thrombolysis in a canine model of coronary artery throm-
bosis (10). We have also reported that the endogenous APC
level is elevated in patients with AMI, and the levels were
higher in cases with unsuccessful thrombolysis, suggesting
that APC generation might be accelerated in response to
the increased thrombin generation in those cases (11). From
these observations, we hypothesized that therapeutic ad-
ministration of exogenous APC might be useful as a
conjunctive therapy to enhance the effects of thrombolysis in
patients with AMI.
To examine this hypothesis, we investigated the effect of
APC conjunctively administered after thrombolysis with
recombinant tissue-type plasminogen activator (t-PA) in
patients with AMI. The effects were compared with those
of conventional conjunctive therapy using unfractionated
heparin in a randomized fashion.
METHODS
The schematic summarization of the study protocol of the
present study is shown in Figure 1.
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Patients. We studied 19 consecutive patients with first
ST-segment–elevated AMI successfully treated with re-
combinant t-PA. Patients were admitted to our institutions
within 6 h after symptom onset. All had ischemic symptoms
lasting 30 min and met the following electrocardiographic
(ECG) criteria: ST-segment elevation 0.1 mV in two or
more limb leads or ST-segment elevation 0.2 mV in two
or more contiguous precordial leads. Written, informed
consent was obtained from each patient and his or her
family. The study protocol was in agreement with the
guidelines of the ethics committee at our institutions.
Thrombolysis. All patients underwent emergent coronary
angiography (CAG) immediately after they were diagnosed
as having AMI. Patients with cardiogenic shock and a
contraindication to thrombolytic therapy (active peptic ul-
ceration, previous intracerebral hemorrhage, surgical oper-
ation, significant trauma, or head injury within the last four
weeks) were excluded from this study, and instead of
thrombolysis, coronary angioplasty was selected for reper-
fusion therapy. All patients received 81 mg oral aspirin and
an intravenous bolus administration of 100 U/kg unfrac-
tionated heparin (heparin sodium, Shimizu Pharmaceutical
Co., Ltd., Shizuoka, Japan) before CAG. After confirming
the total occlusion of an infarct-related coronary artery,
corresponding to the ST-segment–elevated leads on the
ECG, the patients underwent thrombolytic therapy with
the recombinant t-PA called alteplase (GRTPA, Tanabe
Seiyaku Co., Ltd., Osaka, Japan). Alteplase was adminis-
tered intravenously at 0.5 to 0.75 mg/kg. Ten percent of the
total dose was administered as an intravenous bolus, fol-
lowed by drip infusion of the rest over 60 min. The
maximum total dose is recommended not to exceed 41.4 mg
(24 million IU). Infusion was stopped when Thrombolysis
In Myocardial Infarction trial flow grade 3, confirmed by
repeated CAG with continuous 12-lead ECG monitoring,
was obtained.
Conjunctive therapy. Patients were randomly assigned to
receive one of the following two intravenous conjunctive
therapies during 48 h after thrombolysis: unfractionated
heparin, 100 to 400 U/kg per day, adjusted to maintain an
activated partial thromboplastin time (aPTT) at 1.5 to 2
times the control level (heparin group, n  10), or human
plasma-derived APC, 0.06 mg/kg per day (APC group, n
9). The randomized conjunctive therapy was begun imme-
diately after the completion of thrombolysis. Table 1 shows
the baseline patient characteristics of the two conjunctive
treatment groups.
Activated protein C. Human plasma-derived APC
(CTC-111) was kindly provided by the Chemo-Sero-
Therapeutic Research Institute (Kumamoto, Japan). The
manufacturing process of APC is briefly described as fol-
lows. Protein C was purified from freshly prepared citrated
human plasma by immunoaffinity chromatography using
the anti-protein C monoclonal antibody column. After
activation of protein C by human thrombin, APC was
purified to homogeneity, essentially as described by Taylor
et al. (12). Purified APC displayed a single peak on sodium
dodecyl sulfate-polyacrylamide gel electrophoresis. The pu-
rified preparation of APC was pasteurized by heating at
65°C for 96 h in a dry state. No significant change was
observed in the crossed immunoelectrophoresis, circular
dichroic spectra, ultraviolet absorption spectrum, and fluo-
rescence spectrum after heat treatment.
Figure 1. Schematic summarization of the study protocol. All patients were treated with a bolus injection of 100 U/kg heparin followed by a drip infusion
of recombinant tissue-type plasminogen activator (alteplase). The patients were then randomly assigned to receive heparin or activated protein C
intravenously for 48 h. AMI  acute myocardial infarction.
Abbreviations and Acronyms
AMI  acute myocardial infarction
anti-PC MAb  anti-human protein C monoclonal
antibody
APC  activated protein C
aPTT  activated partial thromboplastin time
BSA  bovine serum albumin
CAG  coronary angiography
ECG  electrocardiogram/electrocardiographic
PAI-1  type 1 plasminogen activator inhibitor
TBS  tris buffered saline
TNF  tumor necrosis factor
t-PA  tissue-type plasminogen activator
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Blood sampling. All patients were treated in the intensive
care unit during conjunctive treatments (48 h). Any evi-
dences of adverse events, including reocclusion of the
recanalized coronary arteries and intra- and/or extracorpo-
real bleeding, were carefully monitored. Venous blood was
collected to detect peak serum creatine kinase (CK) and
CK-MB levels, and following coagulation and fibrinolytic
parameters; plasma levels of t-PA antigen, PAI activity,
APC antigen and aPTT. Blood sampling was performed on
hospital admission (pretreatment) and 4, 8, 12, 24, 48, and
72 h after the start of conjunctive treatments. At the time of
sampling, the initial 3 ml blood was discarded, and the
subsequent 2 ml venous blood was collected in a sequential
manner into an evacuated tube containing 0.3 mol/l benza-
midine for measurement of APC, and 3 ml venous blood
was collected into an evacuated tube containing 0.5 ml
sodium citrate (0.13 mol/l, pH 7.5) for measurement of
t-PA antigen, PAI activity, and aPTT. All blood samples
were centrifuged at 3,000 rpm for 10 min at 4°C, and
divided plasma was stored at 80°C until analyzed.
Measurements of t-PA, PAI, APC, and aPTT. Plasma
t-PA antigen levels were measured by commercially avail-
able enzyme-linked immunosorbent assay kits produced by
Diagnostica Stago, Inc. (Francoville, France) (13). Intra-
and interassay coefficients of variation in this assay were
2.4% and 4.7%, respectively. The control value for t-PA
antigen in our laboratory (n  35) was 5.8  1.7 ng/ml
(mean  SD).
Activity levels of PAI were also measured by commercial
chromogenic single-point poly-D-lysine–stimulated assay
kits produced by Biopool Inc. (Umeå, Sweden) (14). Intra-
and interassay coefficients of variation in this assay were
9.4% and 11.4%, respectively. The control value for PAI
activity in our laboratory (n  35) was 5.4  4.1 IU/ml
(mean  SD).
Plasma APC levels were measured by enzyme capture
assay with slight modifications of the method previously
reported by Gruber and Griffin (15). An enzyme capture
assay for APC was performed as follows: polystyrene balls
were dipped in anti-human protein C monoclonal antibody
(anti-PC MAb; JTC-4) (16) in phosphate-buffered saline
(20 mg/ml) and incubated at 4°C overnight. Immobilization
was terminated by rinsing the balls three times, followed by
coating them with 1% bovine serum albumin (BSA)/
phosphate-buffered saline at 4°C for two days. Plasma
samples were diluted at 1:160 with 0.5% BSA/tris buffered
saline (TBS). Standard APC, which was purified by affinity
purification from human plasma using immobilized anti-PC
MAb, was kindly provided by the Chemo-Sero-
Therapeutic Research Institute. The APC standards were
prepared at concentrations of 0.2, 0.1, 0.05, 0.02, 0.01, and
0.005 g/ml, with protein C-deficient pooled normal hu-
man plasma diluted at 1:160 with 0.5% BSA/TBS. Each
sample and the APC standards (400 l) were incubated in
the anti-PC MAb-fixed balls. After incubation at 37°C for
2 h, the balls were washed twice with TBS and then
incubated with 400 l of 0.05 mol/l tris-HCl buffer (pH
8.5) containing a fluorogenic peptide substrate (Peptide
Institute Inc., Osaka, Japan) at 4°C overnight (17). The
enzyme–substrate reaction was terminated by adding 1 ml
of 0.01 mol/l acetic acid, and the fluorescence intensity was
measured (excitation 380 nm, emission 460 nm). Intra- and
interassay coefficients of variation in this assay were 8.1%
and 3.5%, respectively. The control value for APC in our
laboratory (n 23) was 1.3  1.4 ng/ml (mean  SD).
The aPTT was determined with an automated clot timer
and commercially available reagents.
Statistical analyses. Because the values obtained from this
study were not normally distributed, all data are shown as
median values [ranges] instead of mean values SD, unless
otherwise noted. Because of the same considerations, non-
parametric tests were used as statistical analyses. The clinical
characteristics between the APC- and heparin-treated
groups were compared using the Mann-Whitney U test for
continuous data, and the chi-square test for frequency data.
The time course of plasma t-PA, PAI, and APC levels and
aPTT in each conjunctive treatment group was analyzed by
a Friedman test followed by a multiple Wilcoxon signed
rank test if H0 was rejected. More specifically, probability
levels were adjusted according to the following formula:
pk  1  (1  po)
k (i.e., the Dunn-Sidak method;
pk  adjusted p values; po  original p values; k  number
Table 1. Baseline Patient Characteristics of the Two Conjunctive Treatment Groups
APC Group
(n  9)
Heparin Group
(n  10)
Age (yrs) 65 (38–73) 60 (49–68)
Female gender 1 (11%) 1 (10%)
Hypertension 6 (67%) 7 (70%)
Diabetes 2 (22%) 2 (20%)
BMI (kg/m2) 24.9 (22.2–27.5) 24.8 (17.1–31.2)
Smokers 6 (67%) 7 (70%)
Total cholesterol (mg/dl) 200 (116–264) 193 (130–257)
Peak CK (U/l) 2,967 (1,072–5,637) 3,303 (1,320–4,550)
Peak CK-MB (U/l) 261 (64–421) 260 (144–400)
Reocclusion of infarct-related coronary arteries 0 1 (10%)
Bleeding complications 0 3 (30%)
Continuous data are shown as the median value (range), and the other data as the number (%) of patients.
APC  activated protein C; BMI  body mass index; CK  creatine kinase.
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of tests made). Those parameters between the two conjunc-
tive treatment groups at a specific sampling point were
analyzed by the Mann-Whitney U test. Probability levels
0.05 were considered significant.
RESULTS
Patient characteristics and clinical course. There were no
significant differences in the baseline patient characteristics
and clinical courses between the two conjunctive treatment
groups (Table 1). Reocclusion of the recanalized infarct-
related coronary arteries was observed in one patient in the
heparin group. The patient complained of chest pain at
about 8 h after the start of heparin, and the ECG revealed
ST-segment re-elevation in the same leads, as recorded on
admission. Rescue coronary angioplasty was performed for
the recanalization of the reoccluded coronary artery. On the
other hand, none of the patients in the APC group had
reocclusion in their recanalized coronary arteries. There
were no adverse side effects, including hemorrhagic compli-
cations in the APC group, although there were two cases of
minor bleeding (one with hematoma at the puncture site
and macroscopic hematuria; the other with macroscopic
hematuria alone), and one case of major bleeding required
surgical repair (postperitoneal hematoma) in the heparin
group. In this way, total adverse events occurred more
frequently in the heparin group than in the APC group (p
 0.033).
Hemostatic parameters. Plasma APC levels (ng/ml) were
significantly increased in the APC group during drip infu-
sion (4 to 24 h, p  0.05 vs. control), and the peak level
reached more than 10 times the control level (2.0 [0.7 to
4.3] to 24.9 [12.9 to 31.5]) at 12 h after the start of
conjunctive therapy. On the other hand, plasma APC levels
were significantly decreased at 8 h (0.9 [0.5 to 4.0] to 0.7
[0.2 to 1.5], p  0.05), as compared with the pretreatment
level in the heparin group (Fig. 2).
In the heparin group, aPTT was significantly prolonged
at 8 h and 12 h, as compared with the same sampling points
in the APC group. An aPTT in the heparin group was
prolonged 4 to 12 h, as compared with the pretreatment
Figure 2. Serial changes in plasma levels of activated protein C (APC)
between the two conjunctive treatment groups. During infusion of APC,
the plasma levels were maintained at 5 to 10 times its control level. *p 
0.05 vs. pre in both treatment groups. †p  0.05 and ‡p  0.01 between
the two groups at each sampling point. The center lines in the columns
show the median value, and the box plots show the ranges between the
25th and 75th percentile values. The bars attached to the columns show
the ranges between the 10th and 90th percentile values. Solid columns 
APC group; open columns  heparin group.
Figure 3. Serial changes in activated partial thromboplastin time (aPTT)
between the two conjunctive treatment groups. The aPTT was significantly
prolonged in the heparin group, though not in the activated protein C
(APC) group. *p  0.05 vs. pre in the heparin treatment group. ‡p  0.01
between the two groups at each sampling point. The center lines in the
columns show the median value, and the box plots show the ranges
between the 25th and 75th percentile values. The bars attached to the
columns show the ranges between the 10th and 90th percentile values.
Solid columns  APC group; open columns  heparin group.
Figure 4. Serial changes in plasma levels of plasminogen activator inhibitor
(PAI) activity between the two conjunctive treatment groups. There is a
significant difference in the time course of PAI activity between the two
groups. Activity of PAI was increased similarly until 8 h in both groups.
Then the level kept increasing until 24 h in the heparin group, although it
was decreasing in the APC group. *p  0.05 vs. pre in both treatment
groups. †p  0.05 between the two groups at each sampling point. The
center lines in the columns show the median value, and the box plots
show the ranges between the 25th and 75th percentile values. The bars
attached to the columns show the ranges between the 10th and 90th
percentile values. Solid columns  APC (activated protein C) group;
open columns  heparin group.
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level, whereas no significant changes were observed in the
APC group (Fig. 3).
Plasma PAI activity (IU/ml) was increased in both groups
on admission (12.7 [1.0 to 30.8] in the heparin group; 9.3
[0.0 to 30.5] in the APC group), as compared with healthy
subjects. In the heparin group, plasma PAI activity was
increased continuously from 8 to 24 h after thrombolysis
and peaked at 24 h (30.9 [11.3 to 38.5], p  0.05 vs.
hospital admission value); on the other hand, it was in-
creased only at 8 and 12 h after thrombolysis (24.1 [3.0 to
31.0] and 17.6 [1.2 to 34.4], p  0.05 vs. admission) in the
APC group. Plasma PAI activity was significantly sup-
pressed in the APC group compared with the heparin group
at 24 and 48 h after thrombolysis (Fig. 4).
Plasma t-PA antigen levels (ng/ml) were significantly
elevated until 8 h in the APC group and until 24 h in the
heparin group. The t-PA antigen levels were significantly
higher in the heparin group than in the APC group at 24
and 48 h (Fig. 5).
Changes in plasma PAI activity at each of six sampling
points from the pretreatment levels had an obvious relation-
ship with those of plasma APC levels, although the rela-
tionship was not so strong. In other words, the more the
plasma APC level increased, the more the plasma PAI
activity decreased (Fig. 6).
DISCUSSION
In this study, for the first time, we showed that adminis-
tration of APC could be a useful conjunctive therapy after
thrombolysis with recombinant t-PA in patients with AMI.
The effects of APC after thrombolysis, at least during first
several hours, might be the overlap effects of both heparin
and APC, because bolus heparin was administered to all the
study patients.
Anticoagulant effects of APC. Reocclusion of the recana-
lized coronary artery in the early phase of AMI occurs 10%
to 20% of patients, and that causes deterioration of the
efficacy of reperfusion therapy (18,19). Protein C is one of
most important physiologic antithrombotic components
(1,2). After activation by thrombin–thrombomodulin com-
plexes on the endothelial cells, APC inactivates factors Va
and VIIIa in the presence of protein S and phospholipids,
which are the main constituents of the plasma membrane of
platelets and endothelial cells (3,4). This means that APC
acts as an anticoagulant at just the sites of thrombus
generation, and it might be more effective for conjunctive
therapy if administered after thrombolysis. In a canine
model of coronary artery thrombosis, APC has superiority
over heparin to suppress thrombotic reocclusion after recan-
alization with recombinant t-PA, without any hemorrhagic
complications (10). The effects of APC were also confirmed
in human AMI cases from the results of this study.
Profibrinolytic effects of APC. Type 1 plasminogen acti-
vator inhibitor is an important controller of net fibrinolytic
activity, and plasma PAI-1 levels are increased in most AMI
cases (20–22). However, in AMI cases with spontaneously
recanalized infarct-related coronary arteries at emergent
CAG on admission, plasma PAI activity was not increased
(21). In a rabbit carotid artery thrombosis model, Fujii et al.
(22) reported that plasma PAI-1 activity was increased after
t-PA–induced recanalization of completely occluded vessels.
On the other hand, we have reported that PAI activity is
increased 4 h after thrombolytic therapy with alteplase and
remains high during the first 24 h, though not in the cases
with angioplasty (23). In this way, it is important to inhibit
PAI-1 elevation in patients with AMI, particularly after
thrombolysis. Activated protein C is known to be a unique
anticoagulant because it enhances clot lysis by inhibiting
PAI-1 activity in endothelial cell cultures and in clot lysis
assay (7,8). Similarly, elevation of PAI activity was signifi-
cantly suppressed by APC in the present study. Further-
more, it is reported that APC inhibited the production of
tumor necrosis factor- (TNF-), which is known to
Figure 5. Serial changes in plasma levels of t-PA antigen. The level was
higher at 24 and 48 h in the heparin group. *p  0.05 vs. pre in both
treatment groups. †p 0.05 and ‡p 0.01 between the two groups at each
sampling point. The center lines in the columns show the median value,
and the box plots show the ranges between the 25th and 75th percentile
values. The bars attached to the columns show the ranges between the
10th and 90th percentile values. Solid columns  APC (activated protein
C) group; open columns  heparin group.
Figure 6. Correlations between changes in plasma PAI activity from the
pretreatment levels and those of plasma activated protein C (APC) levels at
each of six sampling points after thrombolysis in the APC group.
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stimulate PAI-1 liberation from endothelial cells (24) and
adipocytes (25), by inhibiting activation of transcriptional
factors such as activator protein-1 and nuclear factor-B
(26). Thus, in addition to the direct inhibition effect on
PAI-1, APC may suppress increasing of PAI-1 through an
inflammatory cytokine (TNF-) in patients with AMI. The
profibrinolytic effects of APC could be contributed to less
potential risk of thrombus formation as compared with
heparin.
Adverse clinical events of conjunctive treatments. In this
study, bleeding complications were observed only in the
heparin group. However, because of a small number of study
patients, it is not possible to derive meaningful insights from
the events. As a matter of fact, aPTT was not so prolonged,
although those events occurred during heparin infusion.
Furthermore, the dose of APC used in this study was drawn
upon from another study on the treatment of coagulopathy
of disseminated intravascular coagulation (27). Further
dose-finding trials would be needed to settle the least
effective dose of APC for AMI patients to minimize
possible bleeding side effects.
Conclusions. We have demonstrated that APC adminis-
tered conjunctively with recombinant t-PA is a safe and
effective regimen in patients with AMI. Because of several
properties other than anticoagulant, including PAI-1 inhi-
bition observed in the present study, APC could be more
promising as a conjunctive therapy, as compared with
conventional anticoagulants such as heparin. A large-scale,
randomized trial with long-term follow-up is necessary to
confirm the possible superiority of APC over other antico-
agulants in patients with AMI.
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